marked.bio

Company

Nuvectis Pharma

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

NXP900 3lorlatinib 1osimertinib 1

Trials

3 of 3 trials shown

  1. Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

    Recruiting Phase 1 Nuvectis Pharma Started 2026Primary completion 2027-08 NCT07784959

    NXP900lorlatinib FDA EU

    Unresectable, metastatic or locally advanced ALK-positive NSCLC.

    ALK fusionALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma

  2. Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

    Recruiting Phase 1 Nuvectis Pharma Started 2025Primary completion 2026-12 NCT07315113

    NXP900osimertinib FDA EU

    Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.

    EGFR exon 19 deletion / L858REGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients

  3. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

    Active, not recruiting Phase 1 Nuvectis Pharma Started 2023Primary completion 2027-03 NCT05873686

    NXP900

    …gene mutation or TYMS, YAP1, YES1, or TAZ1 gene amplification, or cholangiocarcinoma with IDH1 or IDH2 mutations.

    IDH1/2 mutationAdvanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma